SHANGHAI and WARREN, N.J., April 7, 2024 /PRNewswire/ -- Laekna (2105.HK) announced that the compan...
* Laekna has developed a proprietary antibody-based drug discovery platform of activated hepatic ...
- A multi-center phase Ib/III study in China and the United States led by ProfessorBinghe Xu, M...
* For the Phase II pivotal trial of Afuresertib (LAE002) + Paclitaxel for platinum-resistant recu...
SHANGHAI and WARREN, N.J. , May 21, 2023 /PRNewswire/ -- Laekna, a clinical-stage biotechnology com...
SHANGHAI and WARREN, N.J., Sept. 6, 2022 /PRNewswire/ -- Laekna, a clinical-stage biotechnology com...
SHANGHAI and WARREN, N.J., May 26, 2022 /PRNewswire/ -- Laekna Therapeutics, a clinical-stage biote...
SHANGHAI and WARREN, N.J., May 18, 2022 /PRNewswire/ -- Laekna Therapeutics (" Laekna"), a clinical-...
SHANGHAI and WARREN, N.J., March 29, 2022 /PRNewswire/ -- Laekna Therapeutics, a clinical-stage glo...
SHANGHAI and WARREN, N.J., Feb. 6, 2022 /PRNewswire/ -- Laekna Group (Laekna Inc and all its direct...
SHANGHAI and WARREN, N.J., Dec. 24, 2021 /PRNewswire/ -- Laekna was invited by NewYorkBIO and the N...
SHANGHAI and WARREN, New Jersey, Sept. 16, 2021 /PRNewswire/ -- Laekna Therapeutics, an emerging in...
SHANGHAI and WAREN, New Jersey, Aug. 26, 2021 /PRNewswire/ -- Laekna Therapeutics announced today t...
SHANGHAI and WARREN, N.J., July 26, 2021 /PRNewswire/ -- Laekna Therapeutics, an emerging innovativ...